


Aloperine: Stereocontrolled Synthesis of Two Stereoisomers and Determination of Absolute Configuration

Arthur D. Brosius and Larry E. Overman*

Department of Chemistry, 516 Physical Sciences 1,
University of California, Irvine, California 92697-2025

Received November 13, 1996

Aloperine, the parent member of a rare family of C₁₅ lupine alkaloids, was first reported in 1935 as a minor component of the seeds and leaves of *Sophora alopecuroides* L.^{1,2} The related plant *Sophora tonkinensis radix* is used effectively by doctors of traditional Chinese medicine in the treatment of inflammatory disorders.³ Recent pharmacological investigations indicate that aloperine displays useful cardiovascular,^{4,5} antiinflammatory, and antiallergic activities.⁶ On the basis of chemical degradation, low-field NMR, and mass spectrometric data, structure **1** was formulated for aloperine in 1975.⁷ Prompted by the promising medicinal activities of aloperine and the opportunity to further explore the participation of nucleophiles in Mannich cyclizations,⁸ we recently initiated a program to synthesize the four diastereomers of **1**.⁹ Herein we report establishment of **2** as the stereochemistry of natural aloperine and total syntheses of aloperine stereoisomers **3** and **4**.



Our approach to aloperine stereoisomers having a cis relationship of the angular methine hydrogen H₆ and the one-carbon bridge was based on seminal studies by Speckamp, who showed that the bridged azatricyclic formates **6** and **7** were formed in high yield by cyclization of α -ethoxy lactam **5** in formic acid (eq 1).¹⁰ However, this mixture of formate regioisomers, which results from unusually fast 1,2-hydride migrations of the intermediate bicyclo[3.3.1]nonyl cation, is not a practical starting point for regiocontrolled elaboration of the additional piperidine

(1) Orechhoff, A.; Proskurnina, N.; Konowalowa, R. *Chem. Ber.* **1935**, 431.

(2) For a brief review, see: Aslanov, K. A.; Kushmuradov, Y. K.; Sadykov, A. S. *Alkaloids (N.Y.)* **1987**, 31, 167.

(3) Long, D. W. *Drugs Future* **1990**, 809.

(4) Zhao, D.; Li, Z.; Yang, X.; Sheng, B. *Zhongcaoyao* **1986**, 17, 170; *Chem. Abstr.* **1986**, 105, 437j.

(5) Li, X.; Wu, Y.; Liu, L.; He, L. *Zhongguo Yaolixue Yu Dulixue Zazhi* **1988**, 2, 72; *Chem. Abstr.* **1988**, 108, 143225m.


(6) Zhou, C.; Gao, H.; Sun, X.; Shi, H.; Liu, W.; Yuan, H.; Wang, Z. *Zhongguo Yaoli Xuebao* **1989**, 10, 360; *Chem. Abstr.* **1989**, 111, 108662s.

(7) Tokachev, O. N.; Monakhova, T. E.; Scheichenko, V. I.; Kabanov, V. S.; Fesenko, O. G.; Proskurnina, N. F. *Khim. Prir. Soedin.* **1975**, 11, 30; *Chem. Abstr.* **1975**, 83, 97667x.


(8) For recent studies of the participation of nucleophiles in Mannich cyclizations of alkynes, see, *inter alia*: (a) Overman, L. E.; Sharp, M. J. *J. Am. Chem. Soc.* **1988**, 110, 612. (b) Lin, N.-H.; Overman, L. E.; Rabinowitz, M. H.; Robinson, L. A.; Sharp, M. J.; Zablocki, J. *J. Am. Chem. Soc.* **1996**, 118, 9062. (c) Caderas, C.; Lett, R.; Overman, L. E.; Rabinowitz, M. H.; Robinson, L. A.; Sharp, M. J.; Zablocki, J. *J. Am. Chem. Soc.* **1996**, 118, 9073.

(9) There have been no reports of synthetic approaches to the aloperine alkaloids. For pioneering syntheses of related C₂₀ *Ormosia* alkaloids, see: (a) Liu, H.-J.; Valenta, Z.; Wilson, J. S.; Yu, T. T.-J. *Can. J. Chem.* **1969**, 47, 509. (b) Liu, H.-J.; Valenta, Z.; Yu, T. T.-J. *Chem. Commun.* **1970**, 1116. (c) Liu, H.-J.; Sato, Y.; Valenta, Z.; Wilson, J. S.; Yu, T. T.-J. *Can. J. Chem.* **1976**, 54, 97.

Scheme 1



ring of **1**. Our recent demonstration of the kinetic participation of iodide in iminium ion–alkyne cyclizations suggested that the presence of this strong nucleophile might prevent the undesired hydride migration.^{8a}



Our studies began with the ene lactam **8**,¹⁰ which was conveniently prepared on a multigram scale from commercially available (\pm)-3-cyclohexene-1-methanol (Scheme 1).¹¹ After some experimentation, we found that exposure of a chloroform solution of **8** and excess tetrabutylammonium iodide to 2 equiv of TfOH at rt provided a single tricyclic iodide **9** (mp 145–145.5 °C), which was isolated in 73–92% yield after purification by chromatography and crystallization.¹² As a prelude to elaboration of the piperidine ring, this intermediate was converted to α -iodo enone **13** as depicted in Scheme 1. Iodide **9** was first dehydrohalogenated with DBU, and the resulting alkene was exposed to *m*-CPBA to provide a single epoxide **10**


(10) Schoemaker, H. E.; Dijkink, J.; Speckamp, W. N. *Tetrahedron* **1978**, 34, 163.

(11) (a) TsCl, pyridine, rt (b) glutarimide, K₂CO₃, 18-crown-6, benzene, reflux (c) NaBH₄, HCl, EtOH, –12 °C (d) TFAA, THF, rt.

(12) No isomers of **9** were detected in the crude cyclization product; however, trace amounts of the tricyclic alkene that is formed upon treatment of **9** with DBU were seen.


in excellent yield. Isomerization of **10** to allylic alcohol **11** was best accomplished by the method of Sharpless.¹³ Oxidation of **11** with tetra-*n*-propylammonium perruthenate-*N*-methylmorpholine *N*-oxide (TPAP-NMO)¹⁴ yielded enone **12**, which was iodinated to deliver α -iodo enone **13**.¹⁵ Introduction of the remaining aminopropyl fragment was then achieved in 88% yield by Suzuki coupling¹⁶ of **13** with borane **14**, which was generated *in situ* by hydroboration of *N*-BOC-allylamine with 1 equiv of 9-BBN-H.^{17,18}

To close the final ring, **15** was treated with TFA to remove the BOC protecting group, and the resulting amine salt was exposed to aqueous NaOH. After 5 min, a single cis-fused tetracycle **16** was produced. However, if base treatment was allowed to proceed for several days, or if tetracycle **16** was re-exposed to aqueous base, a 4:1 mixture of tetracyclic imine **18** and trans-fused tetracycle **19** was formed (eq 2).¹⁹ Treatment of crude **16** with



LiAlH₄ furnished a diamino alcohol ($J_{16,17} = 10.8$ Hz), which was selectively protected on nitrogen by reaction with 2,2,2-trichloroethyl chloroformate (Troc-Cl)²⁰ to provide **17** in 70% overall yield from **15**. Finally, syn dehydration of the equatorial alcohol with POCl₃ and pyridine at 100 °C, followed by cleavage of the Troc functionality with 10% Cd-Pb,²¹ afforded **3**. The ¹H NMR spectrum of this *syn-anti* isomer was not consistent with the published spectrum of aloperine.^{7,22}

Tricyclic enone **12** also proved to be a useful intermediate for preparing the *syn-syn* aloperine isomer **4** (Scheme 2).²² Our approach to constructing the piperidine ring drew upon the observation that imine **18** was the thermodynamic product of base-promoted cyclization of the primary amine derivative of **15** (eq 2). To exploit this thermodynamic preference in the synthesis of **4**, isomeric enone **20** was required. This intermediate was accessed by nucleophilic epoxidation of enone **12**, followed by Wharton rearrangement of the derived β -epoxide²³ and oxidation of the resulting crude allyl alcohol with TPAP-



NMO.¹⁴ The resulting enone **20** was iodinated and cross-coupled with borane **14** to afford enone **22**. When **22** was deprotected with TFA and the crude product exposed to NaOH in MeOH for 24 h at rt, imine **23** was produced as virtually the sole product. Without purification, this intermediate was reduced stereoselectively with NaBH₄ from the convex β -face to provide **24** in essentially quantitative yield from **21**. Finally, reduction of **24** with LiAlH₄ provided *syn-syn* aloperine isomer **4**, whose ¹H NMR spectrum was also not consistent with that of aloperine.⁷

Shortly after initiating the synthesis of **4**, we obtained a sample of natural aloperine **2**, which was converted to the crystalline dihydrochloride monohydrate salt, mp 280 °C dec. Single-crystal X-ray analysis of this material demonstrated that natural aloperine was the *anti-syn* isomer and established that the absolute configuration was 6*R*,7*R*,9*R*,11*S* as depicted in **2**.^{24–26}

In summary, this study demonstrates that iodide can be employed to control the outcome of *N*-acyliminium ion-alkene cyclizations. Using this approach, racemic aloperine stereoisomers **3** and **4** were prepared in stereocontrolled fashion in 12–13 steps and 13–27% overall yield from ene amide **8**. An enantioselective synthesis of aloperine and preliminary pharmacological characterization of **3** and **4** will be described in due course.

Acknowledgment. This research was supported by grants from the NIH (HL-25854) and through graduate fellowships to A.D.B. from Pfizer Research and the Department of Education. We particularly thank Professors Chongchu Zhou and Zhang Qi-Ming for providing samples of natural aloperine, Dr. J. Ziller for the single-crystal X-ray analysis of 2·2HCl·H₂O, and Dr. Matthew Abelman for initially drawing our attention to aloperine.

Supporting Information Available: Experimental procedures and characterization data for new compounds reported in Schemes 1 and 2, copies of ¹H–¹H COSY spectra for **16** and **19**, and copies of ¹H (500 MHz) and ¹³C (125 MHz) spectra for **2** (31 pages).

JO9621231

(24) Absolute configuration was assigned by refinement of the Flack parameter.²⁵

(25) Flack, H. D. *Acta Crystallogr.* **1983**, *A39*, 876.

(26) The authors have deposited atomic coordinates for **2** with the Cambridge Crystallographic Data Centre. The coordinates can be obtained, on request, from the Director, Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge, CB2 1EZ, UK.

(13) Sharpless, K. B.; Lauer, R. F. *J. Am. Chem. Soc.* **1973**, *95*, 2697.

(14) Griffith, W. P.; Ley, S. V. *Aldrichim. Acta* **1990**, *23*, 13.

(15) Johnson, C. R.; Adams, J. P.; Braun, M. P.; Senanayake, C. B. W.; Wovkulich, P. M.; Uskokovic, M. R. *Tetrahedron Lett.* **1992**, *33*, 917.

(16) Miyaura, N.; Suzuki, A. *Chem. Rev.* **1995**, *95*, 2457.

(17) Kabala, G. W.; Li, N.-S.; Pace, R. D. *Synth. Commun.* **1995**, *25*, 2135.

(18) To our knowledge, this transformation is the first example of coupling an α -iodo enone with a nitrogen-containing borane partner. For related precedents, see: (a) Johnson, C. R.; Braun, M. P. *J. Am. Chem. Soc.* **1993**, *115*, 11014. (b) Narukawa, Y.; Nishi, K.; Onoue, H. *Tetrahedron Lett.* **1996**, *37*, 2589.

(19) The stereochemistry of tetracycles **16** and **19** was determined by ¹H–¹H COSY experiments. Copies of these spectra are provided in the Supporting Information. The constitution of imine **18** was established by ¹H and ¹³C NMR analyses.

(20) Windholz, T. B.; Johnston, D. B. R. *Tetrahedron Lett.* **1967**, 2555.

(21) Dong, Q.; Anderson, C. E.; Ciufolini, M. A. *Tetrahedron Lett.* **1995**, *36*, 5681.

(22) The terms *syn-anti* and *syn-syn* refer to the orientation of the angular methine hydrogens H₆ and H₁₁, respectively, with respect to the methano bridge.

(23) (a) Di Grandi, M. J.; Coburn, C. A.; Isaacs, R. C. A.; Danishefsky, S. J. *J. Org. Chem.* **1993**, *58*, 7728. (b) Maas, D. D.; Blagg, M.; Wiemer, D. F. *J. Org. Chem.* **1984**, *49*, 853. (c) Wharton, P. S.; Bohlen, D. H. *J. Org. Chem.* **1961**, *26*, 3615.